Clinical trials: PSMA PET-Positive Castration-Resistant Prostate Cancer
PSMA PET-Positive Castration-Resistant Prostate Cancer
Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)
This is a four-part study evaluating the safety and efficacy of a PSMA-directed radioantibody (rosopatamab tetraxetan, conjugated to either In-111 or Ac-225).
- Trial name
- NCT06549465
- Testing
- In-111 rosopatamab tetraxetan, 45 kBq/kg Ac-225 rosopatamab tetraxetan, 45 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan
- Where
- 9 sites in United States
- Volunteers
- 93 people
- Sponsor
- Convergent Therapeutics
Metastatic Prostate Adenocarcinoma, PSMA PET-Positive Castration-Resistant Prostate Cancer
Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer
KuPSMALu-trial is an observational study for patients treated with 177LuPSMA-I\&T in Kuopio University Hospital, Finland. Study focuses on efficacy, safety and biomarker research.
- Trial name
- KuPSMALu (NCT06850545)
- Where
- Finland
- Volunteers
- 150 people
- Sponsor
- Kuopio University Hospital
PSMA PET-Positive Castration-Resistant Prostate Cancer
Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer
Evaluating the safety and antitumor efficacy of 177Lu-LNC1011
- Trial name
- NCT06809426
- Testing
- 177Lu-LNC1011
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Affiliated Hospital of Jiangnan University
Metastatic Castration Resistant Prostate Cancer, 68Ga-PSMA PET/CT Positive
Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)
Radiometabolic Therapy (RMT) with 177Lu PSMA 617 in advanced castration resistant prostate cancer (CRPC): efficacy and toxicity evaluation
- Trial name
- LU-PSMA (NCT03454750)
- Testing
- 177Lu-PSMA
- Where
- Italy
- Volunteers
- 143 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS